AAPL   383.09 (+0.45%)
MSFT   213.85 (+0.48%)
FB   242.59 (-0.41%)
GOOGL   1,511.07 (+0.50%)
AMZN   3,127.56 (+1.51%)
CGC   16.02 (-1.90%)
BABA   261.15 (+1.34%)
TSLA   1,375.74 (+0.72%)
T   29.65 (-2.66%)
F   5.88 (-3.45%)
GILD   74.86 (-0.99%)
DIS   116.21 (-0.39%)
BAC   22.52 (-2.51%)
AAPL   383.09 (+0.45%)
MSFT   213.85 (+0.48%)
FB   242.59 (-0.41%)
GOOGL   1,511.07 (+0.50%)
AMZN   3,127.56 (+1.51%)
CGC   16.02 (-1.90%)
BABA   261.15 (+1.34%)
TSLA   1,375.74 (+0.72%)
T   29.65 (-2.66%)
F   5.88 (-3.45%)
GILD   74.86 (-0.99%)
DIS   116.21 (-0.39%)
BAC   22.52 (-2.51%)
AAPL   383.09 (+0.45%)
MSFT   213.85 (+0.48%)
FB   242.59 (-0.41%)
GOOGL   1,511.07 (+0.50%)
AMZN   3,127.56 (+1.51%)
CGC   16.02 (-1.90%)
BABA   261.15 (+1.34%)
TSLA   1,375.74 (+0.72%)
T   29.65 (-2.66%)
F   5.88 (-3.45%)
GILD   74.86 (-0.99%)
DIS   116.21 (-0.39%)
BAC   22.52 (-2.51%)
AAPL   383.09 (+0.45%)
MSFT   213.85 (+0.48%)
FB   242.59 (-0.41%)
GOOGL   1,511.07 (+0.50%)
AMZN   3,127.56 (+1.51%)
CGC   16.02 (-1.90%)
BABA   261.15 (+1.34%)
TSLA   1,375.74 (+0.72%)
T   29.65 (-2.66%)
F   5.88 (-3.45%)
GILD   74.86 (-0.99%)
DIS   116.21 (-0.39%)
BAC   22.52 (-2.51%)
Log in

NASDAQ:CTXRCitius Pharmaceuticals Stock Price, Forecast & News

$1.28
-0.02 (-1.53 %)
(As of 07/9/2020 01:06 PM ET)
Add
Compare
Today's Range
$1.24
Now: $1.29
$1.34
50-Day Range
$0.80
MA: $0.99
$1.45
52-Week Range
$0.40
Now: $1.29
$1.97
Volume939,308 shs
Average Volume5.97 million shs
Market Capitalization$58.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Read More
Citius Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.84 per share

Profitability

Net Income$-15,560,000.00

Miscellaneous

Employees7
Market Cap$58.07 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

How has Citius Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Citius Pharmaceuticals' stock was trading at $0.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTXR shares have increased by 114.2% and is now trading at $1.2850. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Citius Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Citius Pharmaceuticals.

When is Citius Pharmaceuticals' next earnings date?

Citius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Citius Pharmaceuticals.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals Inc (NASDAQ:CTXR) released its earnings results on Thursday, May, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.03. View Citius Pharmaceuticals' earnings history.

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Shares of Citius Pharmaceuticals reverse split on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CTXR?

2 equities research analysts have issued twelve-month price targets for Citius Pharmaceuticals' shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Citius Pharmaceuticals' stock price to reach $5.50 in the next year. This suggests a possible upside of 328.0% from the stock's current price. View analysts' price targets for Citius Pharmaceuticals.

Has Citius Pharmaceuticals been receiving favorable news coverage?

Media headlines about CTXR stock have been trending negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Citius Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Citius Pharmaceuticals.

Who are some of Citius Pharmaceuticals' key competitors?

What other stocks do shareholders of Citius Pharmaceuticals own?

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the following people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 74)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 72)
  • Mr. Jaime Bartushak, CFO, Chief Accounting Officer & Principal Financial Officer (Age 51)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 64)
  • Mr. Andrew Scott, VP of Corp. Devel.

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.29.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $58.07 million. Citius Pharmaceuticals employs 7 workers across the globe.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is www.citiuspharma.com.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.